Horizon Therapeutics PLC (NASDAQ:HZNP) gapped up prior to trading on Wednesday . The stock had previously closed at $31.59, but opened at $33.88. Horizon Therapeutics shares last traded at $35.13, with a volume of 3,106,374 shares trading hands.

Several equities analysts recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Zacks Investment Research cut shares of Horizon Therapeutics from a “buy” rating to a “hold” rating and set a $31.00 price target on the stock. in a research report on Tuesday, October 29th. Jefferies Financial Group raised their price target on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Bank of America reaffirmed a “buy” rating and issued a $45.00 price target on shares of Horizon Therapeutics in a research report on Tuesday. Finally, BidaskClub cut shares of Horizon Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 31st. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $38.36.

The company’s 50-day simple moving average is $36.22 and its 200 day simple moving average is $31.34. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 0.87. The stock has a market cap of $6.46 billion, a P/E ratio of 94.95, a PEG ratio of 1.46 and a beta of 1.07.

In other Horizon Therapeutics news, insider Jeff Kent sold 3,545 shares of Horizon Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $36.50, for a total transaction of $129,392.50. Following the transaction, the insider now owns 121,988 shares of the company’s stock, valued at approximately $4,452,562. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Brian K. Beeler sold 6,716 shares of Horizon Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $35.00, for a total transaction of $235,060.00. Following the transaction, the executive vice president now directly owns 77,917 shares in the company, valued at approximately $2,727,095. The disclosure for this sale can be found here. In the last three months, insiders have sold 198,308 shares of company stock worth $7,021,835. Insiders own 4.10% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Lisanti Capital Growth LLC raised its holdings in shares of Horizon Therapeutics by 13.3% in the 3rd quarter. Lisanti Capital Growth LLC now owns 233,865 shares of the biopharmaceutical company’s stock worth $6,368,000 after purchasing an additional 27,395 shares during the period. California Public Employees Retirement System raised its holdings in shares of Horizon Therapeutics by 49.7% in the 3rd quarter. California Public Employees Retirement System now owns 387,522 shares of the biopharmaceutical company’s stock worth $10,552,000 after purchasing an additional 128,634 shares during the period. Mirador Capital Partners LP bought a new stake in shares of Horizon Therapeutics in the 4th quarter worth approximately $596,000. Columbus Circle Investors raised its holdings in shares of Horizon Therapeutics by 33.9% in the 4th quarter. Columbus Circle Investors now owns 924,645 shares of the biopharmaceutical company’s stock worth $33,472,000 after purchasing an additional 234,097 shares during the period. Finally, AMI Asset Management Corp bought a new stake in shares of Horizon Therapeutics in the 4th quarter worth approximately $11,317,000. 90.13% of the stock is currently owned by hedge funds and other institutional investors.

About Horizon Therapeutics (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Article: Why is cost of goods sold important?

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.